Literature DB >> 32297224

International Valuation Protocol for the EQ-5D-Y-3L.

Juan M Ramos-Goñi1,2, Mark Oppe3,4, Elly Stolk4, Koonal Shah5,6, Simone Kreimeier7, Oliver Rivero-Arias8, Nancy Devlin5,9.   

Abstract

The EQ-5D-Y-3L is a generic, health-related, quality-of-life instrument for use in younger populations. Some methodological studies have explored the valuation of children's EQ-5D-Y-3L health states. There are currently no published value sets available for the EQ-5D-Y-3L that are appropriate for use in a cost-utility analysis. The aim of this article was to describe the development of the valuation protocol for the EQ-5D-Y-3L instrument. There were several research questions that needed to be answered to develop a valuation protocol for EQ-5D-Y-3L health states. Most important of these were: (1) Do we need to obtain separate values for the EQ-5D-Y-3L, or can we use the ones from the EQ-5D-3L? (2) Whose values should we elicit: children or adults? (3) Which valuation methods should be used to obtain values for child's health states that are anchored in Full health = 1 and Dead = 0? The EuroQol Research Foundation has pursued a research programme to provide insight into these questions. In this article, we summarized the results of the research programme concluding with the description of the features of the EQ-5D-Y-3L valuation protocol. The tasks included in the protocol for valuing EQ-5D-Y-3L health states are discrete choice experiments for obtaining the relative importance of dimensions/levels and composite time-trade-off for anchoring the discrete choice experiment values on 1 = Full Health and 0 = Dead. This protocol is now available for use by research teams to generate EQ-5D-Y-3L value sets for their countries allowing the implementation of a cost-utility analysis for younger populations.

Entities:  

Mesh:

Year:  2020        PMID: 32297224     DOI: 10.1007/s40273-020-00909-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  28 in total

1.  Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults.

Authors:  Donna Rowen; Clara Mukuria; Philip A Powell; Allan Wailoo
Journal:  Pharmacoeconomics       Date:  2022-03-16       Impact factor: 4.981

2.  A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets.

Authors:  Donna Rowen; Clara Mukuria; Emily McDool
Journal:  Pharmacoeconomics       Date:  2022-07-13       Impact factor: 4.558

3.  Valuing EQ-5D-Y: the current state of play.

Authors:  N Devlin; T Pan; S Kreimeier; J Verstraete; E Stolk; K Rand; M Herdman
Journal:  Health Qual Life Outcomes       Date:  2022-07-06       Impact factor: 3.077

4.  In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives.

Authors:  Stefan A Lipman; Brigitte A B Essers; Aureliano P Finch; Ayesha Sajjad; Peep F M Stalmeier; Bram Roudijk
Journal:  Pharmacoeconomics       Date:  2022-10-18       Impact factor: 4.558

5.  Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Authors:  David J Mott; Koonal K Shah; Juan Manuel Ramos-Goñi; Nancy J Devlin; Oliver Rivero-Arias
Journal:  Med Decis Making       Date:  2021-03-18       Impact factor: 2.583

6.  Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.

Authors:  Takeru Shiroiwa; Shunya Ikeda; Shinichi Noto; Takashi Fukuda; Elly Stolk
Journal:  Med Decis Making       Date:  2021-03-23       Impact factor: 2.583

Review 7.  Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework.

Authors:  Scott D Grosse; Alex R Kemper; Lisa A Prosser
Journal:  Pediatrics       Date:  2021-07       Impact factor: 9.703

8.  'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.

Authors:  Mimmi Åström; Helen Conte; Jenny Berg; Kristina Burström
Journal:  Qual Life Res       Date:  2022-02-24       Impact factor: 3.440

9.  How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year-old children?

Authors:  Janine Verstraete; Andrew Lloyd; Des Scott; Jennifer Jelsma
Journal:  Health Qual Life Outcomes       Date:  2020-05-24       Impact factor: 3.186

10.  EQ-5D-Y Value Set for Slovenia.

Authors:  Valentina Prevolnik Rupel; Marko Ogorevc
Journal:  Pharmacoeconomics       Date:  2021-02-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.